Daraxonrasib Breakthrough for Pancreatic Cancer | Boston News

A groundbreaking new drug, daraxonrasib, is rewriting the odds for pancreatic cancer patients—potentially doubling life expectancy and halting tumor growth where chemotherapy failed. Targeting the elusive KRAS mutation, this experimental therapy, already available through expanded access, has brought miracles to patients like Lazar Mandinov and Rob Martell, who now experience pain relief, renewed hope, and extended time with loved ones. While not a cure and resistance can emerge, this breakthrough marks a historic leap forward in treating one of medicine’s toughest cancers. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/bd3fea36f5396e2c